medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2014, Número 2

<< Anterior Siguiente >>

Residente 2014; 9 (2)


Células troncales leucémicas: una mirada rápida

Avilés-Vázquez S, Moreno-Lorenzana DL, Chávez-González A

Idioma: Español
Referencias bibliográficas: 30
Paginas: 44-50
Archivo PDF: 276.28 Kb.


RESUMEN

Evidencia creciente de los últimos ańos indica que el comportamiento tumoral está gobernado por la presencia de células troncales que comparten diversas características con las células troncales normales de cada tejido pero que al mismo tiempo muestran particularidades que las han colocado como un tema de gran interés para la investigación científica básica y para el área clínica. En esta revisión, se presenta un panorama general de la biología de las células troncales tumorales, tomando como modelo las leucemias mieloides, que a la fecha son el sistema mejor descrito y que ha mostrado la pauta para el estudio de células troncales presentes en tumores sólidos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mayani H, Flores-Figueroa E, Pelayo R, Montesinos JJ, Flores-Guzmán P, Chávez-González A. Hematopoyesis. Cancerología. 2007; 95-107.

  2. Pelayo R, Santa-Olalla J, Velasco I. Células troncales y medicina regenerativa. Universidad Nacional Autónoma de México. 2011.

  3. Bonnet D, Dick J. Human acute leukemia is organized as a hierarchy that originates from primitive hematopoietic cell. Nature. 1997; 3 (7): 730-737.

  4. Dazzi F, Capelli D, Hasserjian R, Cotter F, Corbo M, Poletti A et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor’s disease: an in vivo model of chronic myelogenous leukemia biology. Blood. 1998; 92 (4): 1390-1396.

  5. Jaras M, Johnels P, Hanse N, Agersam H, Tsapogos P, Rissler M et al. Isolation and killing of candidate chronic myelod leukemia stem cell by antibody targeting of IL-1 receptor accesory protein. PNAS. 2010; 107 (37): 16280-16285.

  6. Dash A, Gilliland DG. Molecular genetics of acute mieloyd leukaemia. Best Pract Res Clin Haematol. 2001; 14: 49-64.

  7. Chávez-González A, Moreno-Lorenzana D, Avilés-Vázquez S, Mayani H. Hematopoietic stem cell in chronic myeloid leukemia. Intech. 2013; 136-154.

  8. Warner JK, Wang JC, Hope KJ, Jin L, Dick J. Concepts of human leukemia develpolment. Oncogene. 2004; 23: 7164-7177.

  9. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009; 12 (4-5): 103-113.

  10. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999; 94 (6): 2056-2064.

  11. Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973; 57 (4): 485-488.

  12. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009; 106 (9): 3342-3347.

  13. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010; 28 (4): 562-569.

  14. Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010; 28 (4): 556-561.

  15. Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2012; 120: 48.

  16. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as fırst-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006; 108 (10): 3262-3270.

  17. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009; 113 (17): 3938-3946.

  18. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379: 1508-1516.

  19. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2 (5): 561-566.

  20. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344 (14): 1031-1037.

  21. Avilés-Vázquez S, Chávez-González A, Mayani H. Inhibidores de cinasas de tirosina (ICT): la nueva revolución en el tratamiento de la leucemia mieloide crónica (LMC). Gac Med Mex. 2013; 149 (6): 646-654.

  22. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011; 152 (5): 524-542.

  23. Cukierman E, Bassi D. The mesenchymal tumor microenvironment: a drug resistant niche. Cell Adhes Migr. 2012; 6 (3): 285-296.

  24. Chávez-González, Avilés-Vázquez, Moreno-Lorenzana, Mayani V. Hematopoietic stem cells in chronic myeloid leukemia. In: Alimoghaddam K (ed). Stem cell biology in normal life and diseases. Intech; 2013. pp. 137-164.

  25. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8 (11): 1018-1029.

  26. Mian AA, Metodieva A, Badura A, Khateb M, Ruimi N, Najajreh Y et al. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer. 2012; 12: 411.

  27. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009; 41 (7): 783-792.

  28. Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med. 2009; 361 (12): 1202-1205.

  29. Peng C, Brain J, Hu Y, Goodrich A, Kong L, Grayzel D et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood. 2007; 110 (2): 678-685.

  30. Guzmán ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007; 110 (13): 4427-4435.




2020     |     www.medigraphic.com